MADRID, Spain—AstraZeneca is still licking its wounds from its July lung-cancer combo flop—and Bristol-Myers Squibb is dreading the possibility of producing a similar result with its own ongoing Op |...

Marking a dramatic step for a partnership aiming to affordably treat Chagas patients, the FDA

After being on the market for 10 years and withdrawn for 7 years, Pfizer’s Mylotarg is set to make its return. | After being on the market for 10 years and withdrawn for 7 years, Pfizer’s Mylotarg is...

After a long wait, Gilead Sciences finally scored its big deal on Monday, picki | Gilead executives didn't disclose much about their CAR-T pricing thoughts after the deal's announcement, but analysts...

Mylan last spring recalled tens of thousands of EpiPen injectors that had been manufactured by a Pfizer unit that were potentially faulty. | Mylan last spring recalled tens of thousands of EpiPen...

Especially after the week Teva’s had, it may need to pay | Especially after the week Teva’s had, it may need to pay up—big time—to land a CEO that can help it turn its fortunes. Now that the strugg...

It wasn’t all that long ago that Lundbeck had fallen on hard times. | It wasn’t all that long ago that Lundbeck had fallen on hard times. But thanks to some new launches—and some new leadership to...

That big generics pricing hit that’s helped lop billions off of Teva’s market cap over the last week? The company knew it was coming—and stayed mum for five weeks. | That big generics pricing hit...

Pfizer today won FDA approval for a new targeted drug for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL). | Pfizer today won FDA approval for a new targeted drug for the...

Perrigo Thursday delivered something that’s gotten pretty scarce as of late: a generics beat. | Perrigo Thursday delivered something that’s gotten pretty scarce as of late: a generics beat. The...

Aegerion may have thought it was in the clear when it agreed to pay $36 million to settle federal cl | A federal judge rejected Aegerion's proposed $36 million marketing settlement with the Justice...

Pfizer is the smartest company in the Dow. | Pfizer is the smartest company in the Dow. That’s according to Talent Growth Advisors' annual assessment of the 30 companies that make up the Dow Jones...

Facing a rash of lawsuits claiming aggressive opioid marketing led to a nationwide epidemic, Purdue Pharma is initiati | Facing a rash of lawsuits claiming aggressive opioid marketing led to a...

Mylan and Biocon today became the first drugmakers to win an FDA approval of a biosimilar of Roche's blockbuster cancer drug Herceptin, a med that raked in $2.5 billion in U.S. | Mylan and Biocon...

In just a few years, pharma's top launches of 2014 have not only amassed huge sales but reshaped treat | In just a few years, pharma's top launches of 2014 have not only amassed huge sales but...

It feels as though we say this every year, but it bears repeating. From CEOs and COOs to division chiefs and venture capital partners, women are taking the lead and making an impact all over the life...

Wednesday, multiple myeloma med Darzalex hit a development milestone, triggering a $20 million payment from Johnson & John | Wednesday, multiple myeloma medication Darzalex hit a development milest...

Eisai, which was hoping the drug cost regulator in England would approve its cancer drug Halaven to treat breast cancer patients whose cancer persists after a single round of chemo, had i | Eisai,...

Even after the Biomedical Advanced Research and Development Authority suspended funding to its Sanofi-partnered Zika vaccine project, the agency continued its financial commitment to Takeda’s proje |...

As Merck & Co. stacks up indications for its cancer-fighter Keytruda, it’s also adding treatment areas to its cancer awareness umbrella campaign. | As Merck & Co. stacks up indications for its...

Clovis Oncology is one step away from a new use for its ovarian cancer drug Rubraca—and with FDA priority review, it could take that step early next year.  | Clovis Oncology is one step away from a...

Teens across the U.S. started getting COVID-19 vaccines this month after Pfizer’s shot. | Teens across the U.S. started getting COVID-19 vaccines this month after Pfizer’s shot nabbed an emergency...

Sanofi is stepping up support for employees with cancer and other critical illnesses,

Months into the COVID-19 pandemic, just two therapies have emerged as FDA-approved emergency therapies for hospitalized patients. | Months into the COVID-19 pandemic, just two therapies have emerged...

Amid the ongoing coronavirus outbreak, Gilead Sciences’ experimental remdesivir has emerged as the most promising candidate against the deadly pathogen. | Gilead's experimental remdesivir has emerged...

With Merck's sales dragging from the pandemic and the company becoming increasingly reliant on immuno-oncology superstar Keytruda, the pharma giant's executive team unvei | Merck said COVID-19 took a...

Politicians, government officials and pharma executives alike have been predicting a COVID-19 vaccine debut | Politicians, government officials and pharma executives alike have been predicting a...

Eli Lilly’s COVID-19 antibody combo already boasts an FDA authorization for patients at a high | Lilly’s COVID-19 antibody combo already boasts an FDA authorization for patients at a high risk of...

Many organizations and companies in the biopharma world have formed alliances to develop drugs and vaccines against the novel coronavirus amid a global pandemic. | Many organizations and companies in...

While some drugmakers have been plagued with COVID-19 vaccine production problems that have led to serious delivery delays, the same can’t be said for BioNTech and its partner Pfizer. | BioNTech and...

Just 14 months after opening an ambitious gene therapy manufacturing facility in Longmont, Colorado, Novartis is closing up shop there. | In opening two plants in the U.S. over the last two years,...

It feels as though we say this every year, but it bears repeating. | It feels as though we say this every year, but it bears repeating: From CEOs and COOs to division chiefs and venture capital...

A new era of breast cancer treatment could be upon us. | A new era of breast cancer treatment may be upon us. With a landmark clinical trial win, AstraZeneca and Daiichi Sankyo could soon open up a...

After turning down Eli Lilly’s Alzheimer’s disease drug donanemab for an accelerated approval last year, the agency has now offered the anti-amyloid therapy—and a competitor to Eisai and Bioge |...

“It took a village to make me.” These words spoken by WeiQing Zhou, who is the cofounder of two biotechs, could apply to almost any of the women on the 2021 Fiercest Women in Life Sciences list. So...

Bypassing patent protections on coronavirus vaccines was one proposal floated in recent months to boost supplies in poor countries. But it’s not a short-term solution and, as some analysts suggest, |...

Facing the prospect of generic competition to respiratory superstar Advair—and as | Facing the prospect of near-term competition to respiratory stalwart Advair, GlaxoSmithKline is pushing to grow new...

Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for side effects—one of them suicide ideation—a study of medi |...

It took a global pandemic to end the nine-year reign of AbbVie’s Humira as the world’s best-selling pharmaceutical product—and the final tally of 2021 sales wasn’t even close. With Pfizer and...

It’s no secret biosimilars haven’t made a big dent in U.S. drug spending. | While some drug pricing experts believe biosimilars won't deliver meaningful savings in the U.S.—and that it's time to...

Ocugen has secured exclusive regional rights to an intranasally delivered COVID-19 vaccine, positioning it to advance an intervention that already has emergency authorization in India toward the ma |...

CDMO giant Catalent

Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles over in March. | Giovanni Caforio, M.D., is lining up a new gig soon after handing all...

Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus, which can be life threatening. | Use of Novo...

In what CEO Albert Bourla, Ph.D., called an update to a top priority at Pfizer, the company on Thursday systemically laid out its new oncology strategy following the $43 billion acquisition of anti |...

As some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibb—hot off a series of rapid-fire acquisitions in 2023—says it still has dealmaking cash to deploy if the right target | As...

The antibody-drug conjugate (ADC) market is emerging as one of the most competitive areas in pharma, with companies such as AstraZeneca, Gilead and Pfizer investing billions into the space. | The...

Even though most people in the U.S. have been eligible for COVID-19 vaccines and boosters for quite some time, children under 5 still don't have vaccine options. | Congress's COVID-19 committee is...

Amid a U.S. | WuXi Biologics has quietly pulled out of the 2024 BIO International Convention in June. The company's withdrawal from the convention comes at a point of heightened tension between...

The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market...

As industries around the globe wrestle with where and how often artificial intelligence (AI) should be implemented in their workflows, biopharma, for one, is proceeding with caution. | As industries...

The pipeline of personalized medicines for blood cancers is fit to burst, GlobalData warns. | There are more than 800 cell therapy prospects currently in the hopper for just five major blood cancers,...

Merck’s $10.8 billion acquisition of Prometheus Biosciences | Merck’s $10.8 billion acquisition of Prometheus Biosciences earlier this year gave the New Jersey company increased diversity in its...

People with food allergies finally have a medicine that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades. | People with food allergies finally have a drug...

San Francisco—Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates | Despite its recent $43 billion acquisition of...

Since it was established in 2017, Cellino Biotech has offered an intriguing approach to stem cell therapy manufacturing, combining biology, laser physics, gene editing tools and machine l | Leaps by...